Explore more
News
AstraZeneca, CSPC
Digest more
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
Cambridge headquartered global pharmaceutical company AstraZeneca took its spending on China plays in the last month to ...
AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
Astrazeneca (AZN) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback